Search
Filter Results
Displaying 11–20 of 805 for “retinitis clinical trial”
-
Mar 20, 2014
UCI Stem-Cell Pioneer Poised to Launch Clinical Trial for RP Patients
Dr. Henry Klassen’s progenitor-based therapy has the potential to rescue a variety of retinal cells — including rods, cones, retinal pigment epithelium and ganglion cells — and, therefore, may save vision in people with a wide range of conditions.
-
Jan 14, 2014
Vision Improvements Reported in Choroideremia Gene Therapy Clinical Trial
Five of six participants in the initial study group have sustained vision improvements in their treated eyes in dim settings.
-
Apr 14, 2015
Need-to-Know Information about Clinical Trials
A primer on what you can expect from clinical trials.
-
Dec 21, 2018
Applied Genetic Technologies Corporation (AGTC), a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase I/II clinical trial.
-
Jun 18, 2020
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Treatment combines gene therapy and a device that generates and delivers retinal code
-
Feb 7, 2018
AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.
Taking place at five locations in the United States, the clinical trial will enroll approximately 15 males with X-linked retinitis pigmentosa caused by mutations in the gene RPGR and will primarily evaluate safety.
-
Jan 13, 2021
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Company also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
Aug 28, 2023
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
The AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
-
Sep 26, 2013
New Imaging Technique May Be Game-Changer for RP Clinical Trials
Known as EZ Width, it holds potential for reducing the time, cost and number of patients needed to determine if a therapy is working in a clinical trial.
-
Mar 12, 2019
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
ProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.